Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
William Hankey et al.
CANCER RESEARCH (2020)
Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
Sirin Saranyutanon et al.
CANCERS (2020)
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
Michael Brave et al.
CLINICAL CANCER RESEARCH (2020)
Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells
Thanakorn Pungsrinont et al.
CELL AND BIOSCIENCE (2020)
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis
Lugeng He et al.
MEDICINE (2020)
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
Siddharth Gupta et al.
HORMONES & CANCER (2020)
Thyroid hormone induces cellular senescence in prostate cancer cells through induction of DEC1
Roland Kotolloshi et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2020)
Interference with the androgen receptor protein stability in therapy-resistant prostate cancer
Gopinath Lakshmana et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies
Sigfred Ian R. Alpajaro et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Tatsuo Sugawara et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Dihydrotestosterone increases the risk of bladder cancer in men
Dorota Gil et al.
HUMAN CELL (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Zaina T. Al-Salama
DRUGS (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
Aging and stress induced β cell senescence and its implication in diabetes development
Na Li et al.
AGING-US (2019)
Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi Fujita et al.
WORLD JOURNAL OF MENS HEALTH (2019)
Darolutamide For Castration-Resistant Prostate Cancer
Diogo A. Bastos et al.
ONCOTARGETS AND THERAPY (2019)
Rapamycin improves healthspan but not inflammaging in nfb1-/- mice
Clara Correia-Melo et al.
AGING CELL (2019)
Apalutamide and its use in the treatment of prostate cancer
Hala T. Borno et al.
FUTURE ONCOLOGY (2019)
Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists
Daniela Roell et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
A new class of AR antagonists?
Annette Fenner
NATURE REVIEWS ENDOCRINOLOGY (2019)
Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen
Dinuka De Silva et al.
SCIENTIFIC REPORTS (2019)
The antiandrogen bicalutamide induces senescence in LNCaP cells and quiescence in Myc CaP cells
Valerie J. Carpenter et al.
CANCER RESEARCH (2019)
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies
Jon K. Obst et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2019)
Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
Ting-Ting Lin et al.
JOURNAL OF CANCER (2019)
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models
Sergio Regufe da Mota et al.
CANCER CELL INTERNATIONAL (2018)
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A. Teply et al.
LANCET ONCOLOGY (2018)
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Anna Mandel et al.
MOLECULAR MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
Hung-Ming Lam et al.
FRONTIERS IN ONCOLOGY (2018)
Apalutamide for the treatment of prostate cancer
Dana E. Rathkopf et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors
Laura Bousset et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Enzalutamide: A Review in Castration-Resistant Prostate Cancer
Lesley J. Scott
DRUGS (2018)
Role of senescence induction in cancer treatment
Shenghui Qin et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2018)
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Cara M. Statz et al.
TARGETED ONCOLOGY (2017)
DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway
Rajeev Singh et al.
ONCOTARGET (2017)
The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review
J. Bitzer et al.
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE (2017)
Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing
Bernadette Carroll et al.
JOURNAL OF CELL BIOLOGY (2017)
Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair.
Maryam Ghashghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Jacky K. Leung et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Non-Genomic Action of Androgens is Mediated by Rapid Phosphorylation and Regulation of Androgen Receptor Trafficking
Qiong Deng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Unmasking Transcriptional Heterogeneity in Senescent Cells
Alejandra Hernandez-Segura et al.
CURRENT BIOLOGY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling
Mohsen Esmaeili et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
SYNTHETIC LETHAL METABOLIC TARGETING OF CELLULAR SENESCENCE IN PROSTATE CANCER WITH THE REPURPOSED DRUG METFORMIN
Johnathon R. McCormick et al.
JOURNAL OF UROLOGY (2016)
The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells
Mohsen Esmaeili et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2016)
Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells
Avigail Dreazen Wittenberg et al.
PLOS ONE (2016)
Testosterone therapy and prostate cancer
Alexander W. Pastuszak et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2016)
Overview on the complexity of androgen receptor-targeted therapy for prostate cancer
Ammad Ahmad Farooqi et al.
CANCER CELL INTERNATIONAL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
Lei Chang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Senescence as a general cellular response to stress: A mini-review
Irina Fridlyanskaya et al.
EXPERIMENTAL GERONTOLOGY (2015)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Alejo Rodriguez-Vida et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
Sven Perner et al.
ONCOTARGET (2015)
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase
Jelani C. Zarif et al.
ONCOTARGET (2015)
Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA
Lori Zboray et al.
CELL REPORTS (2015)
Amino acids and autophagy: cross-talk and co-operation to control cellular homeostasis
Bernadette Carroll et al.
AMINO ACIDS (2015)
An update on enzalutamide in the treatment of prostate cancer
Axel S. Merseburger et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Merritt P. Edlind et al.
ASIAN JOURNAL OF ANDROLOGY (2014)
Androgen receptor antagonists for prostate cancer therapy
Christine Helsen et al.
ENDOCRINE-RELATED CANCER (2014)
Molecular alterations and emerging targets in castration resistant prostate cancer
D. Lorente et al.
EUROPEAN JOURNAL OF CANCER (2014)
Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway
Julia Roediger et al.
MOLECULAR CANCER (2014)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells
Wiebke Hessenkemper et al.
MOLECULAR ENDOCRINOLOGY (2014)
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
X. Yuan et al.
ONCOGENE (2014)
Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
John M. Kokontis et al.
PLOS ONE (2014)
Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells
G. Castoria et al.
CELL DEATH & DISEASE (2014)
Src: marker or actor in prostate cancer aggressiveness
Virginie Vlaeminck-Guillem et al.
FRONTIERS IN ONCOLOGY (2014)
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer
Ian G. Mills
NATURE REVIEWS CANCER (2014)
Aging, Cellular Senescence, and Cancer
Judith Campisi
ANNUAL REVIEW OF PHYSIOLOGY, VOL 75 (2013)
Computational and Functional Analysis of the Androgen Receptor Antagonist Atraric Acid and Its Derivatives
Maria Papaioannou et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
Hae Yun Nam et al.
AUTOPHAGY (2013)
Programmed Cell Senescence during Mammalian Embryonic Development
Daniel Munoz-Espin et al.
CELL (2013)
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Jean Hoffman-Censits et al.
CLINICAL CANCER RESEARCH (2013)
Posttranslational Modification of the Androgen Receptor in Prostate Cancer
Travis van der Steen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Emerging roles of RB family: New defense mechanisms against tumor progression
Paola Indovina et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
Dominick G. A. Burton et al.
PLOS ONE (2013)
Low serum testosterone levels are predictive of prostate cancer
Luigi Mearini et al.
WORLD JOURNAL OF UROLOGY (2013)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Androgen receptor coregulators: Recruitment via the coactivator binding groove
Dennis J. van de Wijngaart et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
Keith F. Decker et al.
NUCLEIC ACIDS RESEARCH (2012)
Androgen Receptor Drives Cellular Senescence
Yelena Mirochnik et al.
PLOS ONE (2012)
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer
John T. Isaacs et al.
PROSTATE (2012)
Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer
Saroj Niraula et al.
HORMONES & CANCER (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Changmeng Cai et al.
CANCER RESEARCH (2011)
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells
Theodore S. Nowicki et al.
CELL CYCLE (2011)
The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth
Daniela Roell et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes
Masako Narita et al.
SCIENCE (2011)
The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
Jean -Philippe Coppe et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth
Manolis A. Fousteris et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
Andrea Alimonti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Michael E. Jung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
1,25-Dihydroxyvitamin D3 and PI3K/AKT Inhibitors Synergistically Inhibit Growth and Induce Senescence in Prostate Cancer Cells
Linara S. Axanova et al.
PROSTATE (2010)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Oleg Tatarov et al.
CLINICAL CANCER RESEARCH (2009)
Molecular mechanisms of castration-resistant prostate cancer progression
Smitha S. Dutt et al.
FUTURE ONCOLOGY (2009)
Autophagy mediates the mitotic senescence transition
Andrew R. J. Young et al.
GENES & DEVELOPMENT (2009)
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth
Maria Papaioannou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Cytoplasmic localization of the androgen receptor is independent of calreticulin
Minh M. Nguyen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
P. McCall et al.
BRITISH JOURNAL OF CANCER (2008)
A Transcription-Independent Function of FOXO1 in Inhibition of Androgen-Independent Activation of the Androgen Receptor in Prostate Cancer Cells
Ping Liu et al.
CANCER RESEARCH (2008)
Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways
Ramesh Narayanan et al.
MOLECULAR ENDOCRINOLOGY (2008)
Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling
Y-J Jeon et al.
ONCOGENE (2008)
Androgen receptor is a tumor suppressor and proliferator in prostate cancer
Yuanjie Niu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Jean-Philippe Coppe et al.
PLOS BIOLOGY (2008)
PI3K/Akt Pathway Activation Attenuates the Cytotoxic Effect of Methyl Jasmonate Toward Sarcoma Cells
Uri Elia et al.
NEOPLASIA (2008)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains
Bekir Cinar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Nongenomic activity of ligands in the association of androgen receptor with Src
Sung Bae Kim et al.
ACS CHEMICAL BIOLOGY (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer:: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
M. Wirth et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Ligand-specific dynamics of the androgen receptor at its response element in living cells
Tove I. Klokk et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity
Sonja Schleich et al.
PLANTA MEDICA (2006)
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
DG McLeod et al.
BJU INTERNATIONAL (2006)
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells *
L Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Antiandrogens prevent stable DNA-binding of the androgen receptor
P Farla et al.
JOURNAL OF CELL SCIENCE (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells
S Baron et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor
H Dotzlaw et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
PK Majumder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor
D Masiello et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation
A Migliaccio et al.
EMBO JOURNAL (2000)
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth
YH Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
